SCHEMBL370384

SCHEMBL370384

COc1ccc(Cn2cc3c(n2)C(C)CCc2sc(Nc4nccc(C)n4)nc2-3)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 3/20 0.43
GRM8 O00222 1/20 0.37
ACHE P22303 5/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
ALDH1A1 P00352 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
KDM4E B2RXH2 1/20 0.33
BACE1 P56817 1/20 0.32
GAA P10253 2/20 0.32
MAPT P10636 2/20 0.32
SYK P43405 1/20 0.32
PSMD14 O00487 1/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368910 0.91 GRM4 (0.42) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL370746 0.89 GRM4 (0.41) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL6837341 0.87 GRM4 (0.41) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL367983 0.85 GRM4 (0.49) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL15260933 0.85 GRM4 (0.39) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL370071 0.84 GRM4 (0.44) GRM4GRM8SMN1; SMN2NPC1PKM
SCHEMBL369588 0.84 GRM4 (0.40) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL15182505 0.83 CYP1A2 (0.37) GRM4ACHESMN1; SMN2ALDH1A1CYP1A2
SCHEMBL15260978 0.83 GRM4 (0.45) GRM4GRM8ACHESMN1; SMN2NPC1
SCHEMBL369405 0.83 GRM4 (0.40) GRM4GRM8ACHESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 GRM4 1/4885GRM8 19/4885ACHE 1201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.